title: Is Intravenous Iron Supplementation Safe to Administer to Patients on Hemodialysis with Active Infection--What Do We Know, and What More Do We Need to Know?
authors.affiliation: Department of Clinical Pharmacy Outcome Services, University of South Carolina, Columbia, South Carolina; Department of Clinical Pharmacy Outcome Studies, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina; Department of Medicine, William Jennings Bryan Dorn Veterans Administration Medical Center, Columbia, South Carolina; Department of Health Policy and Management, Arnold School of Public Health, Columbia, South Carolina; Division of Cancer Prevention and Control, Hollings National Cancer Institute Designated Cancer Center, Charleston, South Carolina; and bennettc@sccp.sc.edu.
authors.forename: Charles Lee
authors.initials: CL
authors.lastname: Bennett
authors.affiliation: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
authors.forename: Terhi
authors.initials: T
authors.lastname: Hermanson
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007501:Iron / Q000008:administration & dosage*; D007676:Kidney Failure, Chronic / Q000401:mortality* / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis
chemical_list: D007501:Iron
keywords: cardiovascular disease; chronic kidney disease; hemodialysis